Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
2018 · Expert Opinion on Drug Discovery · 122 citations
https://doi.org/10.1080/17460441.2019.1546691
F
Frank I. Tarazi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
150
Papers
7.2K
Citations
46
h-index
98
i10-index
Frank I. Tarazi is an academic researcher from Harvard University. The author has contributed to research in topics: Neurotransmitter Receptor Influence on Behavior & Neuroscience and Neuropharmacology Research & Receptor Mechanisms and Signaling. The author has an h-index of 46, co-authored 128 publications.
ORCID: 0000-0001-6839-9378Papers by this author
worksLocalization of ionotropic glutamate receptors in caudate-putamen and nucleus accumbens septi of rat brain: Comparison of NMDA, AMPA, and kainate receptors
1998 · Synapse · 83 citations
https://doi.org/10.1002/(sici)1098-2396(199810)30:2<227::aid-syn13>3.0.co;2-z
The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder
2016 · Expert Opinion on Drug Discovery · 72 citations
https://doi.org/10.1517/17460441.2016.1160051
Novel antidepressant drugs: Beyond monoamine targets
2021 · CNS Spectrums · 71 citations
https://doi.org/10.1017/s1092852921000791
Effects of risperidone on glutamate receptor subtypes in developing rat brain
2008 · European Neuropsychopharmacology · 61 citations
https://doi.org/10.1016/j.euroneuro.2008.08.010
Vitamin D Supplementation Ameliorates Severity of Major Depressive Disorder
2019 · Journal of Molecular Neuroscience · 58 citations
https://doi.org/10.1007/s12031-019-01461-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat